Gara Jalqabaatti › Saree Oljoo › Florida › Orlando
Qorannoo klinikaalii Saree Oljoo Orlando, FL keessatti
Qorannoo 23 Saree Oljoo f Orlando fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth, Altamonte Springs · Miili 9 fagaatti
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Advent Health, Orlando
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · Miili 16 fagaatti
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024), Altamonte Springs · Miili 9 fagaatti
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Namoota walitti qabaa jiraSadarkaa 3
- Orlando Health Cancer Institute ( Site 0011), Orlando
- AdventHealth Altamonte Springs ( Site 0021), Altamonte Springs · Miili 9 fagaatti
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Altamonte Springs · Miili 9 fagaatti
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044), Altamonte Springs · Miili 9 fagaatti
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth Altamonte Springs, Altamonte Springs · Miili 9 fagaatti
- Clermont Oncology Center, Clermont · Miili 24 fagaatti
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- AdventHealth Altamonte Springs, Altamonte Springs · Miili 9 fagaatti
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth Orlando Infusion Center, Orlando
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute - Lake Nona Florida, Orlando
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Cancer Centers of Florida, Ocoee · Miili 10 fagaatti
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Namoota walitti qabaa jiraSadarkaa 3
- Advent Health - Orlando, Orlando
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
- AdventHealth Altamonte, Altamonte Springs · Miili 9 fagaatti
- fi 1 dabalataa
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Namoota walitti qabaa jiraSadarkaa 3
- AdventHealth Orlando, Orlando
- Orlando Health Cancer Institute, Orlando
- AdventHealth Altamonte, Altamonte Springs · Miili 9 fagaatti
- fi 1 dabalataa
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Florida Cancer Specialists, Orlando
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Namoota walitti qabaa jiraQorannoo ilaalaa
- AdventHealth East Altamonte Oncology and Hematology, Altamonte Springs · Miili 9 fagaatti
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Adventhealth, Orlando
UCF MammoChat: Image Repository
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- University of Central Florida, Orlando
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Florida Cancer Specialists, Orlando
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Exelixis Clinical Site #8, Orlando
Qorannoo Saree Oljoo magaalota biroo keessatti
- New York City, NYQorannoo 136
- Houston, TXQorannoo 126
- Boston, MAQorannoo 112
- Nashville, TNQorannoo 81
- Los Angeles, CAQorannoo 73
- Edison, NJQorannoo 68
- St. Louis, MOQorannoo 64
- Queens, NYQorannoo 64
- Durham, NCQorannoo 64
- Chicago, ILQorannoo 59
- Philadelphia, PAQorannoo 56
- Dallas, TXQorannoo 55
Qorannoo biroo Orlando keessatti
- Kansara Qara'a Non-Small CellQorannoo 44
- ObesityQorannoo 32
- Kansara MetastatikiiQorannoo 29
- Baayyee UlfaataaQorannoo 27
- Dhukkubaa AlzheimerQorannoo 25
- Sukkaraa Gosa 2Qorannoo 25
- Saree (Gosoota Hunda)Qorannoo 24
- Kansarii OvariiQorannoo 22
- Colitis UlcerativeQorannoo 22
- Dhibee QaraQorannoo 21
- Kansarii ColorectalQorannoo 19
- Dhibee Gaddii GuddaaQorannoo 19
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.